TDSPharm Co

TDSPharm Co Intangible Assets

The Intangible Assets of TDSPharm Co (464280.KQ) as of Nov 5, 2026 is 288.26 M KRW. In the previous year, Intangible Assets was 198.23 M KRW — a change of 45.42% (higher).

Intangible Assets

288.26 MKRW

YoY

45.42%

Last updated:

Intangible Assets of TDSPharm Co is 2024 288.26 M KRW. Intangible Assets of TDSPharm Co was 2023 198.23 M KRW. It decreases by 45.42% higher compared to the previous year.

The TDSPharm Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2022
157.17 M KRW
Jan 1, 2023
198.23 M KRW
Jan 1, 2024
288.26 M KRW
The TDSPharm Co Intangible Assets history
YEARIntangible AssetsYoY
288.26 MKRW+45.42%
198.23 MKRW+26.13%
157.17 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TDSPharm Co Stock analysis

What does TDSPharm Co do? TDSPharm Co Ltd generates revenue through the manufacture and sale of synthetic drug displays and other finished drugs, as well as medical equipment sales. The company operates in the pharmaceutical manufacturing sector with a focus on synthetic drug displays and finished pharmaceutical products. Its e-commerce business complements traditional sales channels for medical equipment and pharmaceuticals. The primary customers include healthcare providers, hospitals, and medical institutions purchasing synthetic drug displays, finished drugs, and medical equipment. The company's product segments are synthetic drug displays, finished drugs, and medical equipment, with e-commerce serving as an additional sales channel for these segments. TDSPharm Co Ltd's revenue streams are derived from three core product categories: synthetic drug displays, finished drugs, and medical equipment. The company's e-commerce platform facilitates direct sales to healthcare institutions and medical facilities. The business model combines traditional manufacturing with digital sales channels, targeting healthcare providers as the main customer segment. The company's operations are centered on pharmaceutical manufacturing and medical equipment distribution, with e-commerce as a supplementary sales method. The company's primary revenue comes from the sale of synthetic drug displays and finished drugs, which are manufactured and sold directly to healthcare institutions. Medical equipment sales form a secondary revenue stream, while the e-commerce business provides an additional channel for all product categories. TDSPharm Co Ltd targets healthcare providers and medical institutions as its main customer base, with product segments focused on pharmaceutical manufacturing and medical equipment distribution. TDSPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TDSPharm Co stock

Intangible Assets of TDSPharm Co is 288.26 M KRW in 2024.

Intangible Assets of TDSPharm Co changed from 198.23 M KRW to 288.26 M KRW, representing a 45.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets TDSPharm Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's TDSPharm Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — TDSPharm Co

All Key Metrics — TDSPharm Co